Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT ID: NCT06805825 Phase: PHASE1 Sponsor: Novelty Nobility, Inc. Status: Recruiting

SUMMARY

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

KEY ELIGIBILITY CRITERIA

- Subjects must meet the following criteria to be eligible for enrollment into the study:
- 1. Histologically or cytologically confirmed locally advanced, metastatic, and/or unresectable GIST, SCLC, ACC, uveal melanoma, NET ChRCC or ccRCC.
- 2. Subjects must have received the following treatment:
- Part A (Dose Escalation):
- i. Treatment with imatinib for GIST (at least one line of therapy with imatinib)
- ii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for c-Kit-associated solid tumors (ACC, uveal melanoma, NET ChRCC or ccRCC)
- Part B (Dose Expansion):
- i. Treatment with imatinib for GIST (at least one line of therapy with imatinib) or
- ii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for Extensive stage SCLC or
- iii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for c-Kit-associated solid tumors (ACC, uveal melanoma, NET or ChRCC or ccRCC).

ENROLLMENT CONTACT

Rashmi Chugh, MD
University of Michigan Hospitals
Ann Arbor, Michigan, United States
Phone: 734-709-2415
Email: rashmim@med.umich.edu

Total sites: 5 | 4 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT06805825) and public sources. Generated by FindMyCure.ai.